Rejuvenate Bio

About Rejuvenate Bio

Rejuvenate Bio focuses on creating ideal treatments for chronic, age-related diseases, addressing the significant health issue affecting 6 in 10 Americans who suffer from at least one chronic disease, which are leading causes of death, disability, and healthcare costs in America.

Products & Services

Human Therapies:Therapies aimed at treating chronic and age-related diseases in humans.

Animal Health Pipeline:Development pipeline for animal health solutions.

Animal Health Gene Therapy Trial:Clinical trials for gene therapy solutions targeting animal health.

Specialties

Gene Therapy Chronic Disease Treatment Age-Related Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4000000 MR: - FA: $4M FAN: 4000000	D: 2024-07-01 FD: 2024-07-01	1 investors

Grant Latest

2024-07-01

$4.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

George Church

Co-Founder and SAB

LinkedIn (Pro only)

K

Katherine High

M.D.

LinkedIn (Pro only)

F

Frank Greenway

Chief Medical Officer

F

Frank L. Greenway

Chief Medical Officer Professor

F

Fabian Kausche

D.V.M.

S

Stephen Chelko

Professor

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Rejuvenate Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised